Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
- 1Department of Biochemistry, Dongguk University College of Medicine, 123 Dongdae-ro, Gyeongju 38066, Republic of Korea
- 2Medical Research Institute, Dongguk University College of Medicine, 123 Dongdae-ro, Gyeongju 38066, Republic of Korea
Abstract
Skeletal muscle aging arises from interacting defects in proteostasis, mitochondrial quality control, inflammatory signaling, neuromuscular integrity, regenerative capacity, and mechanical–metabolic plasticity, and may culminate in sarcopenia. Circular RNAs (circRNAs) are plausible regulators and biomarker candidates, but most evidence derives from developmental myogenesis, expression profiling, or non-aging atrophy models. This critical review organizes the literature around skeletal muscle aging and applies a four-level framework encompassing discovery, mechanistic support, in vivo causality, and functional intervention. We assess human linkage, species, treatment timing, locus of action, and endogenous or engineered modality separately. circSnd1 and circDdb1 currently provide the strongest combination of functional preclinical evidence and association with aged human skeletal muscle. circFUT10, circBBS9, circNEB, and circGLIS3 define less mature regenerative, discovery, histological, or muscle-quality domains. Non-aging atrophy studies, including circTmeff1 and engineered circmiR-29b, test whether proposed mechanisms remain active under defined catabolic stress. Human blood and serum-vesicle studies provide discovery-level associations with strength or mobility, but clinical validation of a circulating circRNA biomarker for sarcopenia remains insufficient. Therapeutic development is constrained by quantitative target credibility, systemic skeletal-muscle exposure, post-onset functional efficacy in aged organisms, safety, reversibility, and independent replication. The field should now prioritize rigorous validation over additional descriptive cataloging.
Related
- Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications
- Sulforaphane as a Therapeutic Target for Sarcopenia in Type 2 Diabetes: Mechanistic Insights and Translational Evidence.
- Long non-coding RNAs in monocyte/macrophage-mediated immune dysregulation and organ injury in sepsis: mechanistic insights and therapeutic potential.
- Dickkopf-3 (DKK3) in cardiovascular diseases: from a stress-responsive biomarker to a potential therapeutic target
- Natural Products and Their Derivatives in Cancer, Cardiovascular disease, and COVID-19: Mechanistic Insights, Formulation Strategies, and Therapeutic Potential
BibTeX
@article{ngo2026circular,
title = {{Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness}},
author = {Thanh Huu Phan Ngo and Wan Lee},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198844},
url = {https://www.mdpi.com/1422-0067/27/19/8844},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
AU - Thanh Huu Phan Ngo
AU - Wan Lee
PY - 2026
DA - 2026/10/03
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198844
UR - https://www.mdpi.com/1422-0067/27/19/8844
AB - Skeletal muscle aging arises from interacting defects in proteostasis, mitochondrial quality control, inflammatory signaling, neuromuscular integrity, regenerative capacity, and mechanical–metabolic plasticity, and may culminate in sarcopenia. Circular RNAs (circRNAs) are plausible regulators and biomarker candidates, but most evidence derives from developmental myogenesis, expression profiling, or non-aging atrophy models. This critical review organizes the literature around skeletal muscle aging and applies a four-level framework encompassing discovery, mechanistic support, in vivo causality, and functional intervention. We assess human linkage, species, treatment timing, locus of action, and endogenous or engineered modality separately. circSnd1 and circDdb1 currently provide the strongest combination of functional preclinical evidence and association with aged human skeletal muscle. circFUT10, circBBS9, circNEB, and circGLIS3 define less mature regenerative, discovery, histological, or muscle-quality domains. Non-aging atrophy studies, including circTmeff1 and engineered circmiR-29b, test whether proposed mechanisms remain active under defined catabolic stress. Human blood and serum-vesicle studies provide discovery-level associations with strength or mobility, but clinical validation of a circulating circRNA biomarker for sarcopenia remains insufficient. Therapeutic development is constrained by quantitative target credibility, systemic skeletal-muscle exposure, post-onset functional efficacy in aged organisms, safety, reversibility, and independent replication. The field should now prioritize rigorous validation over additional descriptive cataloging.
SN - 1422-0067
ER -